Cerenome, Inc. (CNSY) updated its corporate presentation on September 30, 2026, covering CNSide diagnostic commercialization and REYOBIQ clinical programs. As of that date, CNSide had 24 commercial ordering institutions and 43 ordering providers; commercial tumor-cell enumeration (TCE) volume was 362 specimens year to date, with 97% from 15 institutions ordering in two or more separate months. The company reported 158 million contracted covered lives and a proprietary reimbursement code effective July 1, 2026. The Medicare rate was expected to take effect January 1, 2027.
Modeled six-month leptomeningeal metastasis care costs were $717,000 under current standard of care, $480,000 with earlier CNSide confirmation and optimized management, and $380,000 with optimized management and favorable treatment-cost assumptions. In a 15-patient Phase 2 study of REYOBIQ, median overall survival was 13 months and median progression-free survival was 11 months, compared with stated standard-of-care figures of 8 and 4 months, respectively. ReSPECT-GBM was enrolling, with Phase 2 enrollment completion in Q4 2026 and topline data projected for the first half of 2027.
Cerenome, Inc. (CNSY) director An van Es-Johansson vested 921 restricted stock units on October 1, 2026, and acquired 921 shares of common stock. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026. An van Es-Johansson held 1,843 common shares directly following the transaction.
Richard J. Hawkins, a director of Cerenome, Inc. (CNSY), had 921 restricted stock units vest on October 1, 2026, and acquired 921 shares of common stock. His reported holdings after the transaction were 2,450 common shares and 1,843 restricted stock units. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. Chief Financial Officer Andrew John Hugh MacIntyre Sims reported three restricted stock unit grants vesting on October 1, 2026, and acquisition of 2,985 common shares. The three tranches were 1,533, 1,165 and 287 shares. Each Restricted Stock Unit represents a contingent right to receive one common share. No Rule 10b5-1 plan is reported.
Cerenome, Inc. (CNSY) reported vesting of 921 restricted stock units for director Howard Clowes on October 1, 2026, with 921 common shares acquired. Following the transactions, Howard Clowes directly held 2,902 common shares and 1,843 RSUs. The RSU grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. CEO and director Marc H. Hedrick reported vesting of three restricted stock unit grants on October 1, 2026, and acquired 6,387, 8,066 and 1,986 shares of common stock, respectively. The grants vest in 12 substantially equal quarterly installments, with schedules beginning on October 1, 2025, April 1, 2026 and July 1, 2026, respectively.
Cerenome, Inc. director Ronald Asbury Andrews reported vesting of 921 Restricted Stock Units on October 1, 2026; each unit represents a contingent right to receive one common share. The transaction also records acquisition of 921 common shares, with reported direct common-stock holdings of 1,843 shares afterward. The grant vests in four substantially equal quarterly installments beginning July 1, 2026.
Cerenome, Inc. (CNSY) director Kyle Guse reported vesting 921 restricted stock units on October 1, 2026, with 921 common shares acquired. Each RSU represents a contingent right to one common share. His reported direct common-stock position following the transaction was 1,843 shares. The grant vests in four substantially equal quarterly installments beginning July 1, 2026.
CERENOME, INC. (CNSY), a Delaware biotechnology company based in Houston, filed a Form D for a private exempt securities offering under Rule 506(b) of Regulation D. The offering includes equity, debt, and rights such as options or warrants.
The notice reports $3,000,000 already sold and $17,000,000 remaining to be sold. CERENOME agreed to issue senior secured convertible notes with aggregate original principal of up to $21,276,596, each carrying an original issue discount of 6.0%. No finders’ fees are reported, and the first sale occurred on September 10, 2026.
Cerenome, Inc. (CNSY) has arranged a senior secured convertible note and royalty-based financing to support its CNS oncology platform and CNSide diagnostics business. The company agreed with an institutional investor to issue senior secured convertible notes with an aggregate original principal amount of $21,276,596, split into Initial Notes of $3,191,489, Second Notes of $2,127,660, and Additional Notes of $15,957,447. The Initial closing is expected on or about September 10, 2026, when Cerenome expects to receive gross proceeds of $3,000,000.
The notes carry a 6.0% original issue discount, accrue interest at 8.0% per year, mature one year after issuance, and are secured by a first‑priority lien on substantially all assets of Cerenome and its subsidiary CNSide. They are convertible into common stock at an initial price of $2.74 per share, with a $0.50 floor and ownership caps of 4.99% (or 9.99% at the investor’s election), plus an exchange cap tied to Nasdaq rules. In default, an alternate, discount-to-market conversion formula applies and redemption premiums, including a 120% cash redemption on a Change of Control, may be triggered.
On the Initial Closing Date, Cerenome and CNSide are expected to enter a Royalty Agreement under which CNSide will pay the investor a quarterly royalty of 2.5% of its gross revenues, capped each quarter at 2.5% of the unpaid note balance, until all note obligations are fully repaid. A Registration Rights Agreement will require Cerenome to submit resale registration statements for conversion shares within set deadlines. Management states that, considering this facility, other facilities, existing cash and expected CNSide sales and cash flow, forecasted cash runway now extends well into 2028.